Welcome to our dedicated page for Pardes Biosciences news (Ticker: PRDS), a resource for investors and traders seeking the latest updates and insights on Pardes Biosciences stock.
Pardes Biosciences, Inc. (PRDS) drives innovation in biotechnology through its novel small molecule therapeutics targeting critical health challenges. This news hub provides investors and industry professionals with essential updates on the company's progress in addressing unmet medical needs.
Access timely information on PRDS' clinical trial developments, strategic partnerships, and regulatory milestones. Our curated collection features press releases covering antiviral research, oncology advancements, and financial updates that shape the company's trajectory in biopharmaceutical innovation.
Key updates include progress reports on preclinical studies, collaboration announcements with leading venture firms, and insights into therapeutic pipeline expansion. Monitor critical developments in drug discovery and commercialization efforts through verified primary sources.
Bookmark this page for streamlined access to Pardes Biosciences' official communications. Regularly updated content ensures stakeholders maintain current awareness of material events influencing the company's position in competitive therapeutic markets.
Pardes Biosciences, Inc. (NASDAQ: PRDS) announced that CEO Thomas G. Wiggans and Chief Scientific Advisor Uri A. Lopatin will present a company overview at the 42nd Annual Cowen Healthcare Conference on March 9, 2022, at 11:10 a.m. PT. This event takes place virtually from March 7-9, 2022. Pardes is developing PBI-0451, a novel oral antiviral for SARS-CoV-2 infections, including COVID-19. A live audio webcast of the presentation will be available on Pardes' website, with an archived replay accessible for 30 days.
Pardes Biosciences, Inc. has appointed Thomas G. Wiggans as the new Chief Executive Officer and Chair of the Board of Directors. Wiggans brings over 40 years of biopharmaceutical experience, including leadership roles in several successful acquisitions. He succeeds Uri Lopatin, M.D., who transitions to Chief Scientific & Strategic Advisor. The company is advancing its antiviral drug candidate, PBI-0451, targeting SARS-CoV-2 and COVID-19.
Pardes Biosciences, Inc. (NASDAQ: PRDS) announced interim clinical data from a Phase 1 trial of its antiviral drug candidate PBI-0451, aimed at treating SARS-CoV-2 infections. The data demonstrated that PBI-0451, administered twice daily, achieves pharmacokinetic exposures likely to ensure potent antiviral activity. The drug has shown good oral bioavailability and was well-tolerated in healthy volunteers, with all adverse events being mild. Pardes plans to host a conference call on February 15, 2022, to discuss these results further.
Pardes Biosciences, Inc. (NASDAQ: PRDS) has announced a virtual investor event on February 15, 2022, at 3 p.m. PT, following its clinical data presentation of the PBI-0451 Phase 1 trial at CROI 2022. PBI-0451 is being developed as a novel direct-acting antiviral drug for treating and preventing SARS-CoV-2 infections, including COVID-19. Interested participants can join via phone or webcast. The event will follow a late-breaking poster presentation on PBI-0451 occurring earlier that day at CROI 2022.
Pardes Biosciences (NASDAQ: PRDS) announced a late-breaker poster presentation at the 29th Conference On Retroviruses And Opportunistic Infections (CROI) 2022, showcasing clinical data from the ongoing Phase 1 trial of PBI-0451, an oral antiviral for SARS-CoV-2. The presentation, titled "PBI-0451: An Orally Administered 3CL Protease Inhibitor of SARS-CoV-2 for COVID-19," is scheduled for February 15, 2022. The trial aims to evaluate PBI-0451's safety, tolerability, and pharmacokinetics in healthy volunteers in New Zealand.
Pardes Biosciences, Inc. (NASDAQ: PRDS) announced the FDA's clearance of its Investigational New Drug (IND) application for PBI-0451, an oral antiviral aimed at treating and preventing SARS-CoV-2 infections. This milestone allows the company to initiate additional Phase 1 clinical trials in the U.S., with global Phase 2/3 studies expected to commence in mid-2022. PBI-0451 is currently being evaluated in a Phase 1 trial in New Zealand to assess safety and pharmacokinetics. The company emphasizes the growing importance of oral antivirals in managing COVID-19 amid the ongoing pandemic.
Pardes Biosciences, a clinical-stage biopharmaceutical company, announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, set for January 12, 2022. CEO Uri A. Lopatin will provide a company overview at 7:30 a.m. PT. The event runs from January 10-13, 2022. Pardes is developing PBI-0451, a novel oral antiviral aimed at treating and preventing SARS-CoV-2 infections, including COVID-19. A live audio webcast will be available on their website, with an archived replay for 30 days.
Pardes Biosciences, Inc. announced the completion of its business combination with FS Development Corp. II, which provided approximately $274 million in gross proceeds. The company will commence trading under the symbol PRDS on the Nasdaq. Pardes is developing PBI-0451, a novel oral antiviral drug candidate aimed at treating SARS-CoV-2 infections. The Phase I clinical trial is ongoing, with results expected in Q1 2022. CEO Uri A. Lopatin expressed a commitment to addressing the COVID-19 pandemic.
FAQ
What is the market cap of Pardes Biosciences (PRDS)?
